3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Recruiting
22
Active not recruiting
10
Completed
7
Not yet recruiting
3
Terminated
1
Suspended
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Genitourinary
1
Conditions
Breast Neoplasms
2
Prostatic Neoplasms
1
Hypogonadism
1
Carcinoma, Ductal
1
Interventions
Specimen Handling
57
Magnetic Resonance Spectroscopy
39
Carboplatin
32
Cyclophosphamide
29
Gemcitabine
28
Bevacizumab
24
pembrolizumab
23
Cisplatin
23
Biopsy
23
Paclitaxel
22
Standard of Care
21
Radiotherapy
21
Drug Therapy
21
fludarabine
20
Injections
20
Capecitabine
20
venetoclax
19
Oxaliplatin
19
Nivolumab
18
Interviews as Topic
17
toripalimab
16
Dexamethasone
16
Blood Specimen Collection
16
Radiosurgery
14
tislelizumab
13
cemiplimab
13
anlotinib
13
Azacitidine
13
Pemetrexed
12
Irinotecan
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Tamoxifen
×
90 days
×
Clear all
NCT07287098
2026-05-22
preEMBER
Eli Lilly and Company
Phase 2
Not yet recruiting
600 enrolled
NCT07535905
2026-04-17
REVIVE
University Health Network, Toronto
Phase 2
Not yet recruiting
96 enrolled
NCT07499999
2026-03-30
BabyTEARS
Dana-Farber Cancer Institute
Phase 2
Not yet recruiting
140 enrolled